RecruitingPhase 2NCT07795749

Ph II Intraperitoneal Paclitaxel + System Therapy in GI Ca w/Peritoneal Carcinomatosis (STOPGAP-B)

Phase II Basket Trial of Intraperitoneal Paclitaxel Plus Systemic Therapy in Gastrointestinal Malignancies With Peritoneal Carcinomatosis (STOPGAP - B)

Sponsor

University of California, Irvine

Enrollment

55 participants

Start Date

Aug 4, 2026

Study Type

INTERVENTIONAL

Conditions

Esophageal Carcinoma Colorectal Adenocarcinoma Small-bowel Adenocarcinoma Appendiceal Adenocarcinoma Gastric Cancer (Diagnosis)Hepatobiliary Carcinoma in Situ

Summary

This is a phase II open-label, basket clinical trial to assess the feasibility of systemic and Intraperitoneal chemotherapy in subjects with Gastrointestinal Malignancies with Peritoneal Carcinomatosis. These are subjects who have a proven primary carcinoma of the digestive tract..

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Paclitaxcel Q3W and a drug called Paclitaxel Q2W for people with appendiceal adenocarcinoma, colorectal adenocarcinoma, and other related conditions. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.